Correlation Between Protagonist Therapeutics and Catalyst Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Protagonist Therapeutics and Catalyst Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Protagonist Therapeutics and Catalyst Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Protagonist Therapeutics and Catalyst Pharmaceuticals, you can compare the effects of market volatilities on Protagonist Therapeutics and Catalyst Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Protagonist Therapeutics with a short position of Catalyst Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Protagonist Therapeutics and Catalyst Pharmaceuticals.

Diversification Opportunities for Protagonist Therapeutics and Catalyst Pharmaceuticals

-0.1
  Correlation Coefficient

Good diversification

The 3 months correlation between Protagonist and Catalyst is -0.1. Overlapping area represents the amount of risk that can be diversified away by holding Protagonist Therapeutics and Catalyst Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Catalyst Pharmaceuticals and Protagonist Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Protagonist Therapeutics are associated (or correlated) with Catalyst Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Catalyst Pharmaceuticals has no effect on the direction of Protagonist Therapeutics i.e., Protagonist Therapeutics and Catalyst Pharmaceuticals go up and down completely randomly.

Pair Corralation between Protagonist Therapeutics and Catalyst Pharmaceuticals

Given the investment horizon of 90 days Protagonist Therapeutics is expected to under-perform the Catalyst Pharmaceuticals. In addition to that, Protagonist Therapeutics is 1.45 times more volatile than Catalyst Pharmaceuticals. It trades about -0.08 of its total potential returns per unit of risk. Catalyst Pharmaceuticals is currently generating about 0.01 per unit of volatility. If you would invest  2,135  in Catalyst Pharmaceuticals on September 19, 2024 and sell it today you would earn a total of  0.00  from holding Catalyst Pharmaceuticals or generate 0.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Protagonist Therapeutics  vs.  Catalyst Pharmaceuticals

 Performance 
       Timeline  
Protagonist Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Protagonist Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's technical and fundamental indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Catalyst Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Weak
Over the last 90 days Catalyst Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Catalyst Pharmaceuticals is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Protagonist Therapeutics and Catalyst Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Protagonist Therapeutics and Catalyst Pharmaceuticals

The main advantage of trading using opposite Protagonist Therapeutics and Catalyst Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Protagonist Therapeutics position performs unexpectedly, Catalyst Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalyst Pharmaceuticals will offset losses from the drop in Catalyst Pharmaceuticals' long position.
The idea behind Protagonist Therapeutics and Catalyst Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Other Complementary Tools

Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Fundamental Analysis
View fundamental data based on most recent published financial statements